Atypical femoral fractures and bone turnover

New England Journal of Medicine

Volumn 365, Issue 13, 2011, Pages 1261-1262

  Jamal, Sophie A ^a   Dion, Natalie ^b   Ste Marie, Louis Georges ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; CREATININE; PARATHYROID HORMONE; PHOSPHORUS; TETRACYCLINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE BIOPSY; BONE RADIOGRAPHY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; FEMUR FRACTURE; HUMAN; INTRAMEDULLARY NAILING; LEG PAIN; LETTER; MORPHOMETRICS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; STRESS FRACTURE; THIGH; VITAMIN BLOOD LEVEL;

EID: 80053379011     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1107029     Document Type: Letter

References (4)

1. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
2. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009;24:1736-40.
3. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38. (Pubitemid 46021497)
4. Bone HG, Hosking D, Devogelaer J-P, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99. (Pubitemid 38339363)